164 related articles for article (PubMed ID: 8135475)
21. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
22. Preoperative serum angiopoietin-2 levels correlate with lymph node status in patients with early gastric cancer.
Jo MJ; Lee JH; Nam BH; Kook MC; Ryu KW; Choi IJ; Kim YW; Bae JM
Ann Surg Oncol; 2009 Jul; 16(7):2052-7. PubMed ID: 19408052
[TBL] [Abstract][Full Text] [Related]
23. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
24. [The role of tumor markers in diagnosing metastases of gastric cancer: preoperative diagnostics (part I)].
Kurygin AA; Maĭstrenko NA; Khrykov GN; Beliak NP
Vestn Khir Im I I Grek; 2009; 168(4):16-9. PubMed ID: 19947409
[TBL] [Abstract][Full Text] [Related]
25. The correlation between pre-operative serum tumor markers and lymph node metastasis in gastric cancer patients undergoing curative treatment.
Li F; Li S; Wei L; Liang X; Zhang H; Liu J
Biomarkers; 2013 Nov; 18(7):632-7. PubMed ID: 24066812
[TBL] [Abstract][Full Text] [Related]
26. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
Kim JH; Jun KH; Jung H; Park IS; Chin HM
Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of preoperative CEA and CA 19-9 levels in resectable gastric cancer.
Dilege E; Mihmanli M; Demir U; Ozer K; Bostanci O; Kaya C; Aksakal O; Sakiz D
Hepatogastroenterology; 2010; 57(99-100):674-7. PubMed ID: 20698248
[TBL] [Abstract][Full Text] [Related]
29. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
30. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
[TBL] [Abstract][Full Text] [Related]
31. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
32. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
[TBL] [Abstract][Full Text] [Related]
33. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
34. Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma.
Ikeguchi M; Katano K; Saitou H; Tsujitani S; Maeta M; Kaibara N
Hepatogastroenterology; 1997; 44(15):866-71. PubMed ID: 9222706
[TBL] [Abstract][Full Text] [Related]
35. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
36. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
37. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the CA 242 tumor antigen as a potential serum marker for colorectal cancer.
Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Carone MD; Aloe S; Tedesco M; Mancini R; Casale V; Carlini S; Casciani CU; Roselli M; Guadagni F
Anticancer Res; 1999; 19(2B):1363-8. PubMed ID: 10365107
[TBL] [Abstract][Full Text] [Related]
39. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
40. Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer.
Lindmark G; Kressner U; Bergström R; Glimelius B
Anticancer Res; 1996; 16(2):895-8. PubMed ID: 8687147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
